Dr Matthew Dale (Co-founder of Concinnity Genetics)2025-08-28T09:00:39
Most gene therapies rely on static DNA promoters to control gene activity, but nature uses far more sophisticated tools. Dr Matthew Dale explores how harnessing RNA-level control could enable treatments that sense and respond in real time, offering unprecedented precision and safety.
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-09-10T08:41:00Z
Sponsored by DNA Genotek Inc.
2026-06-29T06:49:00
Contributor Laura Alvarez, Drug Target Review
2024-02-08T11:07:39
Sponsored by Samplix ApS
2026-08-11T07:02:00
Contributor Professor Joseph C. Wu, Drug Target Review
2026-07-15T07:00:00
Contributor Dr Nick Lynch, Dr Raminderpal Singh
2025-09-18T12:00:00
Sponsored by Benchling
2025-07-30T08:00:00
Sponsored by Wuxi Biologics
Site powered by Webvision Cloud